MetaCap

Cardiol Therapeutics Inc. Class A (CRDL)

NASDAQ: CRDLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.8626-0.0201 (-2.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRDL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$110.14M
EPS (TTM)
-$0.24
52-week range
0.8417 – 2.34
Day range
0.8417 – 0.8952
Volume / Avg
552.97K / 1.20M
Beta
—

52-week range

$0.8417$2.34

CRDL stock today

Cardiol Therapeutics (CRDL) closed at $0.8626 on Nov 20, down 2.28% (-$0.0201), versus the S&P 500's 3.70% decline. Trading was light, with 552.97K shares changing hands, about 46% of the average daily volume. Shares are 63.1% below their 52-week high of $2.34, set on Sep 9, 2026 and 2.5% above the 52-week low of $0.8417, near the bottom of the past year's range.

CRDL is down 9.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.3%. Cardiol Therapeutics has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cardiol Therapeutics

Company profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. David G. Elsley MBA
Headquarters
Oakville, ON
Employees
18

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$8.41+874.96%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.95High $10.80

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.09 vs $-0.06
Surprise
-50.00%

CRDL news

All CRDL news

Cardiol Therapeutics peers

Health Care sector
CRDL peer companies
CompanyPrice% ChgMarket capCompare
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs CRDL
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs CRDL
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs CRDL
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs CRDL
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs CRDL
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs CRDL
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs CRDL
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs CRDL

Indexes, lists and sector

Cardiol Therapeutics stock FAQ

What is Cardiol Therapeutics's stock price today?

CRDL last traded at $0.8626 as of Nov 20, 4:00 PM EST, down 2.28% on the day. Prices are delayed at least 15 minutes.

Who is Cardiol Therapeutics's CEO?

Mr. David G. Elsley MBA is the chief executive officer of Cardiol Therapeutics Inc. Class A, which has about 18 employees.

What is the CRDL 52-week high?

The 52-week high for CRDL is $2.34 and the 52-week low is $0.8417. The stock is currently 63.1% below its high.

Compare CRDL